1. Home
  2. ADPT vs GNW Comparison

ADPT vs GNW Comparison

Compare ADPT & GNW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Adaptive Biotechnologies Corporation

ADPT

Adaptive Biotechnologies Corporation

N/A

Current Price

$28.51

Market Cap

4.6B

Sector

Health Care

ML Signal

N/A

Logo Genworth Financial Inc

GNW

Genworth Financial Inc

N/A

Current Price

$10.08

Market Cap

3.7B

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
ADPT
GNW
Founded
2009
1871
Country
United States
United States
Employees
624
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Life Insurance
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
4.6B
3.7B
IPO Year
2019
2004

Fundamental Metrics

Financial Performance
Metric
ADPT
GNW
Price
$28.51
$10.08
Analyst Decision
Strong Buy
Buy
Analyst Count
9
1
Target Price
$17.78
$10.50
AVG Volume (30 Days)
1.8M
3.5M
Earning Date
05-05-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
63.89
N/A
EPS
N/A
0.24
Revenue
$276,976,000.00
$7,301,000,000.00
Revenue This Year
$3.98
N/A
Revenue Next Year
$22.72
N/A
P/E Ratio
N/A
$41.88
Revenue Growth
54.77
0.08
52 Week Low
$12.00
$7.84
52 Week High
$28.72
$10.69

Technical Indicators

Market Signals
Indicator
ADPT
GNW
Relative Strength Index (RSI) 73.65 48.63
Support Level $23.73 $9.74
Resistance Level N/A $10.20
Average True Range (ATR) 1.06 0.22
MACD 0.37 -0.04
Stochastic Oscillator 97.40 30.68

Price Performance

Historical Comparison
ADPT
GNW

About ADPT Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.

About GNW Genworth Financial Inc

Genworth Financial Inc is a diversified insurance holding company that provides various mortgage and life insurance products. The company has four main operating business segments: Enact, Closed Block segment, and Corporate and Other. The company's product portfolio includes various financial products such as traditional life insurance, mortgage insurance, fixed annuities, and variable annuities. The majority of the revenue is generated by the Enact segment. The company earns the maximum of its revenue in the United States.

Share on Social Networks: